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The accuracy of different methods for the quantitation of hepatitis C virus in plasma was measured with
samples from individuals infected with different genotypes and by using RNA transcripts of predetermined
concentrations. Highly reproducible results were observed upon repeat testing of samples by both the original
version of the Chiron branched-DNA (bDNA) assay (Quantiplex RNA assay; bDNA-1) and the currently
available version (Quantiplex HCV RNA 2.0 assay; bDNA-2). A greater variability was observed in the Roche
Monitor assay (correlation coefficient of 0.537, compared with 0.942 and 0.964 for the bDNA-1 and bDNA-2
assays, respectively). Significant differences in the efficiency of detection of genotypes 1, 2, and 3 were observed
for the bDNA-1 and Roche Monitor assays, whereas the bDNA-2 assay and nested PCR at limiting dilution
were able to quantify genotypes with equal sensitivity. By quantifying RNA transcripts of different genotypes,
the sensitivities of the Roche Monitor assay for sequences of the type 2 and type 3 transcripts were estimated
to be 11 and 8% of those achieved for genotype 1. When correction factors based upon these results and those
from quantitation of circulating viral RNA sequences in samples from blood donors were used, the genotype-
specific differences in virus load in samples from blood donors were no longer observed, consistent with
previous studies with corrected values from the bDNA-1 assay. These results suggest that many of the previous
studies evaluating the effect of genotype and virus load on the response to interferon using methods such as
the Roche Monitor assay and other competitive PCR methods require reinterpretation. Differences in efficiency
of quantitation should be taken into account in future investigations of the relationship between genotype and
virus load.
Quantitation of hepatitis C virus (HCV) RNA sequences in
plasma and more recently in liver has become a valuable di-
agnostic tool for the pretreatment evaluation of patients un-
dergoing treatment with interferon and in the subsequent
monitoring of their response (8). For example, several studies
have described a decreased likelihood of achieving a long-term
response to interferon treatment in individuals with a high
pretreatment virus load in plasma (1, 12, 19–22, 28). This
difference was shown to be independent of other pretreatment
variables that also influenced response, such as severity of liver
disease and virus genotype (19–21, 28).
Several studies have found that the virus load of patients
infected with type 1b was higher than in patients infected with
type 2a or 2b, and it has been argued that this difference may
therefore, at least in part, account for the increased probability
of achieving a long-term response with genotypes 2 and 3 (15,
17, 22, 28). Clearly, such analyses require that the assays used
to determine virus load are equally sensitive for each genotype,
but there is evidence that this was not the case for the original
branched-DNA (bDNA) assay (Quantiplex HCV RNA assay;
Chiron Corporation [referred to as bDNA-1 in this study]).
Quantitation by the bDNA-1 assay of known amounts of RNA
transcripts revealed a twofold reduction in the efficiency of
detection of type 3 transcripts compared with those of type 1
(5). This and subsequent work (9) led to a recent proposal to
correct raw data from the bDNA-1 assay by a factor of 2 for
type 3 infections and by a factor of 3 for type 2 infections (14).
Quantitation of genotypes 4, 5, and 6 was similar to that of
genotype 1 (9).
Using these corrected values for the bDNA-1 assay, we re-
cently found that there was no difference in median virus loads
between any of the six genotypes in HCV-infected blood do-
nors from different geographical regions (25). A similarly de-
signed study found no difference in virus loads among geno-
types 1 to 3 among patients with chronic hepatitis under
assessment for interferon treatment (14). The implication of
these findings is that the observed differences between geno-
types in response to treatment are independent of virus load,
although virus load may remain an independent predictor of
response.
The currently available version of the bDNA assay (Quan-
tiplex HCV RNA 2.0 assay [referred to as bDNA-2]) has been
redesigned to allow equivalent quantitation of all genotypes
(9). In the current study, we have measured the accuracy of
quantitation of different HCV genotypes with this assay and
compared it with that of the bDNA-1 assay, a commercially
available competitive PCR system (Roche Monitor), and an
in-house method based upon limiting dilution PCR with
nested primers from the highly conserved 59 noncoding re-
gion (59NCR). These results have enabled a more detailed
evaluation of the interrelationship between virus load and ge-
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notype and their relative importance to disease severity and in
predicting response to treatment.
MATERIALS AND METHODS
Samples. Ninety-one plasma samples from HCV-infected, PCR-positive Scot-
tish blood donors were analyzed for HCV RNA levels. Samples were repeatedly
reactive on screening for antibodies to HCV with a third-generation screening
assay (Ortho; Abbott), confirmed positive with RIBA-2 or RIBA-3 supplemen-
tary assays and PCR positive with a nested PCR based upon amplification of
sequences from the 59NCR (4, 18). Samples were aliquoted and stored at 2408C
and were only frozen and thawed twice prior to testing. Consecutive samples
were selected to provide suitable numbers of each genotype (31 type 1 [25 type
1a, 6 type 1b], 29 type 2 [all type 2b], and 31 type 3 [all type 3a]). HCV genotype
was determined by restriction fragment length polymorphism analysis of se-
quences amplified from the 59NCR (7).
Three commercial assays for the detection of HCV RNA were used: the
Quantiplex HCV RNA assay (bDNA-1), the Quantiplex HCV RNA 2.0 assay
(bDNA-2), and the Roche Monitor assay. These assays were performed strictly
according to the manufacturer’s instructions. Unamplified HCV RNA was de-
tected in the bDNA-1 and bDNA-2 assays by hybridization to a labelled probe
and amplification of the detection signal. The Roche Monitor assay is based
upon reverse transcription and amplification of the HCV RNA with primers
from the 59NCR in the presence of a competitor RNA derived from a virus of
genotype 1. Both the competitor and the sample DNA were detected by hybrid-
ization to a probe in a colorimetric assay.
For the in-house limiting dilution method (23, 24), viral RNA was extracted
from 100 ml of plasma by incubation with proteinase K (1 mg/ml) and sodium
dodecyl sulfate (0.55%) in the presence of polyadenylic acid (40 mg/ml) and
purified by phenol-chloroform extraction. HCV RNA was precipitated in 70%
ethanol and resuspended in 25 ml of diethylpyrocarbonate (DEPC)-treated wa-
ter. Five microliters of this solution was reverse transcribed and amplified by
nested PCR with primers specific for the 59NCR. Limiting dilution of cDNA was
then carried out in a series of 10-fold steps, which allowed quantification to
within 1 log. The quantitation was further refined by the addition of a specific
volume of cDNA to a number of replicate PCRs which would give a Poisson
distribution of positive and negative samples and therefore allow the concentra-
tion of HCV cDNA to be determined. The previously established efficiency of
5% for the reverse transcription step was assumed in this assay (30).
Quantitation of HCV RNA transcripts. HCV transcripts of all three genotypes
were provided by J. Detmer, Chiron Diagnostics, Emeryville, Calif.). The meth-
ods used for their synthesis and quantitation have been described elsewhere (5,
9). Briefly, to assess the quality of the preparations, HCV RNA transcripts were
electrophoresed on 1.5% formaldehyde gels and scanned on an Ambis 4000
radioanalytic imager (Ambis, Ino, San Diego, Calif.). The preparations of the
HCV RNA transcripts used in the study contained less than 3% free nucleotides
and were composed of at least 80% full-length transcripts. Three independent
analytical methods were used to quantify the transcripts. These included phos-
phate determination (6), measurement of A260, and hyperchromicity analysis
(27). Preparations of HCV RNA transcripts were measured in triplicate by each
of the three methods, and quantification results agreed within 10%. Transcript
RNA was diluted in DEPC-treated water (N 3 105 and N 3 106 transcripts) or
a buffer containing 10 mM Tris, 1 mM EDTA, and 100 mM NaCl for the N 3
107 transcripts before analysis and stored at 2708C until use. Transcripts were
quantified in the bDNA-2 and Roche Monitor assays.
RESULTS
Quantitation of HCV RNA in four different quantitation
assays. Plasma samples were obtained from a total of 91 HCV-
infected blood donors who were viremic as determined by a
nested PCR with primers from the 59NCR (4, 18). HCV ge-
notypes were identified by restriction fragment length poly-
morphism analysis of amplified sequences (7). The study group
was selected to include approximately equal numbers of each
of the three common genotypes in Western Europe and com-
prised 31 individuals infected with type 1 (25 type 1a, 6 type
1b), 29 infected with type 2b, and 31 infected with type 3a.
Fresh plasma samples were aliquoted to ensure that all
quantitative assays were carried out with samples that had
been frozen and thawed only twice. HCV RNA was quantified
with the bDNA-1 and bDNA-2 assays, the Roche Monitor
assay, and an in-house quantitation method based upon limit-
ing dilution of cDNA (Table 1). A total of 25 samples were
negative in the bDNA-1 assay, with a cutoff of 0.35 3 106
copies of RNA/ml (27%), while 17 (19%) were negative in the
bDNA-2 assay (cutoff sensitivity of 0.2 3 106 copies of RNA/
ml). Among these, 17 samples were negative in both assays (1
type 1, 5 type 2, and 6 type 3) and 8 were negative in the
bDNA-1 assay only (2 type 1, 3 type 2, and 3 type 3). In the
Roche Monitor assay and limiting dilution assays, six samples
(four type 2, two type 3) were below the cutoff (approximately
1,000 copies of RNA/ml). Samples below the cutoff for each
assay were assigned the virus load of the cutoff. This approxi-
mation did not affect nonparametric methods used to analyze
the results.
There was a significant correlation between assays for the
measurement of virus load measured for each (Table 2). For
TABLE 1. Quantitation of HCV RNA in plasma samples in four assays
Genotype (n) Virus loada bDNA-1 bDNA-2 RocheMonitor
Limiting
dilution
1 (31) Median 3.28 3.35 0.98 2.4
Minimum ,0.35 ,0.2 0.1 0.11
Maximum 23.59 23.51 6.80 49
2 (29) Median 0.96 3.59 0.28 2.4
Minimum ,0.35 ,0.2 ,0.001 ,0.001
Maximum 12.04 32.75 19 24.5
Ratio to type 1b 0.29 1.0 0.29 1.0
P valuec 0.003 0.906 (NS) 0.022 0.917 (NS)
3 (31) Median 0.85 1.09 0.09 2.4
Minimum ,0.35 ,0.2 ,0.001 ,0.001
Maximum 20.67 71.04 3.71 34
Ratio to type 1 0.26 0.33 0.09 1.0
P value 0.015 0.459 (NS) ,0.001 0.850 (NS)
a Virus load is expressed in 106 copies of RNA/ml.
b Ratio of median virus load to that of genotype 1 samples.
c Probability of differences in virus load between genotypes occurring by chance (Mann-Whitney U test [one-way analysis of variance]). Significant differences (P ,
0.05) are underlined. NS, not significant.
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example, over the range of quantitations of the bDNA-2 assay
(.0.2 3 106 copies of RNA/ml), positive correlation coeffi-
cients were observed upon comparison with the bDNA-1,
Roche Monitor, and limiting dilution methods for quantita-
tion. Similarly, nonparametric tests of correlations produced a
high correlation coefficient upon pairwise comparison of each
test (all values, P , 0.001 [Table 2]). The best correlation for
all genotypes was between the results of the bDNA-1 and
bDNA-2 assays, with a correlation coefficient of 0.866 (Table
2). This was also observed when virus loads in samples of
different genotypes were analyzed separately (Table 2). Cor-
relation coefficients for virus load among type 2 samples were
lower than those observed for the type 1 or type 3 samples in
all assays.
One factor that influences how well test results correlate is
the reproducibility of the assays. To investigate this, we tested
between 7 and 27 samples in duplicate in the four assays with
separate aliquots of sample and, where possible, with different
manufacturers’ batches of reagents (Table 3). The most repro-
ducible assay was the bDNA-2 assay, with a high correlation
coefficient upon repeat testing of 20 samples (0.939) and a low
standard deviation of 60.052 log10 values (95% confidence
interval, approximately 26%). The least reproducible assay was
the Roche Monitor assay, with a correlation efficient of 0.769
and a standard deviation of 60.311 log10 value (95% confi-
dence interval, approximately 400%) upon repeat testing (Ta-
ble 3). The corresponding values for the bDNA-1 and limiting
dilution assays were 0.942 6 0.1022 and 0.941 6 0.184, respec-
tively.
Virus load and genotype. In each assay, a wide range of virus
loads was observed among donors infected with each genotype
(Table 1 and Fig. 1). Median values calculated for these dis-
tributions differed between different quantitation assays. For
example, among the type 1-infected donors, median values of
3.28, 3.35, 0.98, and 2.4 were observed for the bDNA-1,
bDNA-2, Roche Monitor, and limiting dilution methods, re-
spectively (Table 1). According to the bDNA-2 and limiting
dilution assays, virus loads were similarly distributed between
other genotypes, with median values of 3.59 and 2.4 for type 2
samples and 1.09 and 2.4 for type 3 samples, respectively.
Using Wilcoxon’s signed-rank test (Mann-Whitney U test), we
observed no significant difference in virus load between donors
infected with types 1, 2, and 3 (Table 1) when samples were
analyzed with the bDNA-2 or limiting dilution assays.
In contrast, significant differences in virus loads between
genotypes were observed with the other assays. In the Roche
Monitor assay, median virus loads for types 2 and 3 were 0.28
and 0.09, 3.3 and 10 times lower than the values calculated for
type 1 samples (P 5 0.022 and P , 0.001, respectively), while
there was no difference between types 2 and 3 (P 5 0.183).
Virus loads measured for the bDNA-1 assay were also different
between genotypes; the type 2 and 3 samples were 3.3 and 4
times lower, respectively, than the type 1 samples (P 5 0.024
and P 5 0.015). The differences in virus load between geno-
types in the bDNA-1 assay can in this case be attributed to the
previously described reduced sensitivity of the bDNA-1 assay
for type 2 and 3 sequences (see below).
The ratios of virus load measured in the bDNA-1, Roche
FIG. 1. Range of HCV RNA levels in plasma samples from blood donors
infected with genotypes 1, 2, and 3 as detected by bDNA-1 (A), bDNA-2 (B),
Roche Monitor (C), and limiting dilution (D) quantitative assays. Cutoff values
for the bDNA-1 assay (0.35 3 106 copies of RNA/ml) are indicated by a solid
line; cutoff values for the bDNA-2 assay (0.2 3 106 copies/ml) are indicated by
a dashed line. Median values for each genotype are indicated by short solid lines.
TABLE 3. Replicate testing of samples in quantitative assays
Assay No. ofreplicates
Log10
variancea
Spearman rank
correlation
coefficient
bDNA-1 22 0.1022 0.942
bDNA-2 20 0.052 0.964
Roche Monitor 7 0.316 0.537
Limiting dilution 9 0.184 0.941
a Expressed as a standard deviation about a log10 mean value.
TABLE 2. Correlation between tests for quantitation of
HCV RNA in type 1, 2, and 3 samples
Genotype and test
Correlation witha:
bDNA-1 bDNA-2 RocheMonitor
Limiting
dilution
Type 1
bDNA-1 1
bDNA-2 0.961 1
Roche Monitor 0.795 0.802 1
Limiting dilution 0.729 0.744 0.612 1
Type 2
bDNA-1 1
bDNA-2 0.870 1
Roche Monitor 0.637 0.662 1
Limiting dilution 0.637 0.557 0.571 1
Type 3
bDNA-1 1
bDNA-2 0.903 1
Roche Monitor 0.784 0.856 1
Limiting dilution 0.755 0.712 0.632 1
All types
bDNA-1 1
bDNA-2 0.866 1
Roche Monitor 0.764 0.698 1
Limiting dilution 0.682 0.711 0.548 1
a Spearman’s rank correlation coefficient (all values, P , 0.001).
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Monitor, and limiting dilution assays to that measured by the
bDNA-2 assay were calculated (Fig. 2 and Table 4). The scat-
ter in values of the ratios reflects both the variance observed
for each assay upon testing of duplicates and differences in the
efficiency of detecting RNA sequences in the two assays. A
particularly wide range of ratios were observed upon compar-
ison of the Roche Monitor assay with the bDNA-2 assay (Fig.
2B), while the smallest range was observed upon comparison
of the bDNA-1 and bDNA-2 assays (Fig. 2A). The ratios for
two of the tests (Roche Monitor and bDNA-1) varied, depend-
ing upon genotype, with type 2 and 3 samples showing ratios
and median ratios consistently lower than those observed for
the type 1 samples (in each case, P , 0.001). In the extreme
case, type 3 samples in the Roche Monitor assay showed a
median ratio approximately eightfold lower (0.063) than that
for type 1 (0.3). In contrast, no significant difference in ratio
was observed upon comparison of limiting dilution with the
bDNA-2 assay (ratios of 0.85, 0.74, and 0.76 for genotypes 1, 2,
and 3, respectively).
Quantitation of HCV RNA transcripts. Three different con-
centrations of HCV RNA of HCV types 1, 2, and 3 were
assayed in the Roche Monitor and bDNA-2 assays to investi-
gate whether these tests differed in their sensitivity for se-
quences of different genotypes (Table 5). These were diluted to
the operating ranges of the quantitative assays as described in
Materials and Methods. The Roche Monitor assay was rela-
tively inefficient at detecting RNA transcripts of all three ge-
notypes. Type 1a sequences were detected with an efficiency of
approximately 13.5%, whereas quantitation of the type 2b and
3a transcripts was even further from the expected values (1.5
and 1.1% efficiency, respectively). The type 2 transcript was
detected with an efficiency 9-fold lower than that of type 1,
while the efficiency of detection of type 3 was reduced by a
factor of 12-fold. The bDNA-2 assay detected transcripts from
each of the three genotypes with much higher efficiency. For
type 1 transcripts, the mean sensitivity was 88% of the expected
value, while for type 3 transcripts, the average was 60% of the
input number of sequences. The type 2 transcripts were de-
tected with an efficiency of approximately half that expected at
the two lower dilutions.
DISCUSSION
This study used a range of quantitative assays to measure
virus load in individuals infected with different HCV geno-
types. Even small genotype-specific differences in the sensitiv-
ity of these assays would have a significant compounding effect
upon statistical analysis of the influence of these and other
variables on disease severity and response to treatment. Al-
though few studies have systematically addressed this issue, it
has been reported that the now superseded bDNA-1 assay
showed a significantly reduced sensitivity for genotypes 2 and 3
(5, 9). As a short-term measure to correct for this difference, it
was suggested that virus loads measured by this assay in type 2
infections should be multiplied by 3 and those of type 3 should
be multiplied by 2 (14). This study confirmed the difference in
sensitivity of this assay for these genotypes (Table 4). Whereas
the bDNA-1 and bDNA-2 assays measured similar virus loads
in type 1 samples (median ratio, 1.04), the ratio between the
bDNA-1 and bDNA-2 assays for type 2 was 0.22 (the expected
value based upon the multiplication factor above would be
0.33), and that between for type 3 was 0.46 (expected value,
0.5).
A more satisfactory solution to the use of multiplication
factors was the modification of the capture and target probes
to remove their genotype dependence. The currently available
version 2 of the assay (Quantiplex HCV RNA 2.0 assay) had
been shown to quantify transcripts of HCV types 1 to 6 with
similar efficiencies (9), and this was confirmed experimentally
with RNA transcripts in the current study (Table 5).
Although we have no a priori knowledge of the actual virus
FIG. 2. Comparison of quantitation of genotypes 1, 2, and 3 by the bDNA-1 (A), Roche Monitor (B), and limiting dilution (C) assays expressed as ratios to levels
determined in the bDNA-2 assay. Median values for each genotype are indicated by short solid lines.
TABLE 4. Efficiency of detection of genotype 1, 2, and 3 sequences
relative to that of the bDNA-2 assay
Genotype (n) Efficiency ofdetection bDNA-1
Roche
Monitor
Limiting
dilution
1 (31) Median 1.04 0.43 0.850
Minimum 0.5 0.028 0.085
Maximum 2.73 1.53 10.9
2 (29) Median 0.25 0.15 0.744
Minimum 0.054 0.001 0.037
Maximum 1.36 3.4 3.18
Ratio to type 1 0.22 0.34 0.86
P valuea ,0.001 ,0.008 0.502 (NS)
3 (31) Median 0.52 0.063 0.76
Minimum 0.173 0.009 0.088
Maximum 1.14 0.26 3.03
Ratio to type 1 0.46 0.15 0.90
P value ,0.001 ,0.001 0.986 (NS)
a Probability of differences in virus load between genotypes occurring by
chance (Mann-Whitney U test [one-way analysis of variance]). Significant differ-
ences (P , 0.05) are underlined. NS, not significant.
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load in the plasma samples from blood donors, equal efficien-
cies of detection of sequences of different genotypes were
implied by the observation of similar virus loads among those
infected with the three genotypes (Table 1). Similarly, no sig-
nificant differences in virus load between genotypes were ob-
served with the bDNA-1 assay once the correction factors were
applied (Table 1 and data not shown). Finally, quantitation
based upon limiting dilution also found similar virus loads
between genotypes (Table 1) and median ratios to the bDNA-2
assay values of 0.85, 0.74, and 0.76 for genotypes 1, 2, and 3,
respectively (Table 4). The comparability between the results
of these three tests argues strongly that no significant differ-
ences in virus load exist between genotypes, consistent with
previous larger surveys of blood donors and patients (13, 25)
and that quantitation by the (corrected) bDNA-1, bDNA-2,
and limiting dilution assays is not influenced by sequence vari-
ation of HCV.
These results contrast strongly with those of the competitive
assay investigated in the current study (Roche Monitor). Sig-
nificantly lower levels of viremia were observed among samples
collected from blood donors infected with genotypes 2 and 3
compared with those infected with genotype 1 (Table 1). The
magnitude of this difference was comparable to that a previous
study of hemophiliacs infected with genotypes 1 to 4 (2). Based
upon the comparison with other quantitative assays in this
study, we propose that the apparent differences in median virus
load between genotypes determined with the Roche assay re-
sulted from unequal quantitation, rather than reflecting true
biological differences between them.
Further evidence for genotype dependence of the Roche
assay comes from quantitation of known amounts of HCV
RNA transcripts of different genotypes (Table 5). Whereas the
bDNA-2 assay showed efficiencies of detection ranging from 44
to 88% for transcripts of different genotypes, the Roche Mon-
itor assay showed generally much reduced levels, particularly
for genotypes 2 and 3 (Table 5). Quantitation of type 2 se-
quences was approximately 11% that achieved for type 1 se-
quences, while type 3 sequences were detected with an effi-
ciency of 8% compared with that of type 1 sequences. We are
currently carrying out a more detailed investigation of the
transcript quantitation in the Roche Monitor assay; however,
these preliminary results do provide approximate correction
factors that might be applied to the results from clinical spec-
imens in a manner analogous to those proposed for the
bDNA-1 assay (14). If the correction factors are applied to the
Monitor results in the current study (i.e., multiplying virus load
by a factor of 9 for type 2 samples and by a factor of 12 for type
3 samples), the previously observed differences in virus load
between genotypes become nonsignificant (type 2 median ratio
to type 1, 2.6; P 5 0.124; and type 3 median ratio to type 1,
1.09; P 5 0.524).
The reduced sensitivity of the Roche assay for sequences of
genotypes 2 and 3 probably originates from mismatches be-
tween the PCR primers and the target HCV. The assay is
based upon competition with the quantitation standard, which
shows a perfect match to the sequences of the primers and
probes used in the assay. The small sequence differences be-
tween the sense primer and target (one mismatch with pub-
lished type 2 sequences and two mismatches with type 3 se-
quences [26]) could potentially have a large impact upon the
relative amounts of sequences transcribed during the exponen-
tial phase of amplification (29). Although the in-house limiting
dilution assay uses primers with similar mismatches, quantita-
tion is unlikely to be affected to the same extent because the
target cDNA sequences are isolated by dilution prior to PCR,
and so are amplified without competition from other se-
quences. Since nested PCR produces large amounts of product
from as little as a single input DNA copy, minor differences in
amplification efficiency resulting from mismatches are unlikely
to influence whether sequences isolated at limiting dilution can
be detected.
Virus load and genotype. Previous studies with the bDNA-1
assay, Roche Monitor assay, and competitive PCR have all
identified significantly higher levels of viremia in type 1 pa-
tients than in type 2 or 3 patients prior to interferon therapy (2,
3, 10, 12, 17). On the basis of these results, it has been pro-
posed that this difference in viral titers accounts, at least in
part, for the poor response to interferon treatment of type
1-infected patients. However, the results of the current study
concur with more recent data based on the use of corrected
bDNA-1 assay values (13, 25) which found no significant dif-
ference in virus load among blood donors or patients infected
with different genotypes. These findings have the important
implication that genotype and virus load must be independent
predictors of the response to interferon (16, 28).
The findings also suggest that there are no major differences
between genotypes in replication rate or susceptibility to im-
mune clearance in untreated patients. This finding is consistent
with previous observations that multiply exposed individuals,
such as hemophiliacs, do not become preferentially infected
with one particular genotype (11). A predominance of type 1
infections in hemophiliacs would be expected if this genotype
replicated to a significantly higher level in vivo.
In summary, we have provided evidence that levels of circu-
latory viremia in type 1, 2, and 3 infections may be quantified
with unequal efficiencies and that the magnitude of this differ-
ence in the Roche Monitor assay is likely to have significant,
confounding effects upon statistical analyses of virus load and
genotype. There is clearly a need to more accurately measure
the difference in sensitivity for a wider range of genotypes,
including type 4, and to apply the resulting correction factors
to the results of the large number of completed or ongoing
clinical studies in which virus load measurements have been
based upon this method. In the future, it may be possible to
correct the primer-target mismatches in the Roche Monitor
assay if that is the cause of the unequal quantitation and
therefore provide a more satisfactory assay for clinical studies.
TABLE 5. Measurement of absolute efficiency of quantitation
assays with RNA transcripts of genotypes 1, 2, and 3
Genotype No. of inputcopiesa
No. of copies of RNA/ml byb:
bDNA-2 Roche Monitor
1 4.4 3 105 7.1 3 105 0.28 3 105
4.4 3 106 3.1 3 106 0.71 3 106
1 3 107 0.33 3 107 0.18 3 107
2 4.4 3 105 2.9 3 105 0.071 3 105
4.4 3 106 1.0 3 106 0.12 3 106
1 3 107 0.39 3 107 0.0017 3 107
3 5.1 3 105 5.0 3 105 0.068 3 105
5.1 3 106 2.3 3 106 0.07 3 106
1 3 107 0.36 3 106 0.0047 3 107
a Transcripts were diluted in DEPC-H2O, except for those at the 1 3 107
concentration, which were diluted in Tris buffer.
b The mean sensitivities (number of copies of RNA per milliliter) of the assays
for genotypes 1, 2, and 3 were as follows: genotype 1, bDNA-2, 0.882; Roche
Monitor, 0.135; genotype 2, bDNA-2, 0.44; Roche Monitor, 0.015; genotype 3,
bDNA-2, 0.6; Roche Monitor, 0.011.
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